Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective

• Egile Nagusiak: Brian Murray (Egilea), Jennifer Miles-Thomas (Egilea), Amy J Park (Egilea), Victor B Nguyen (Egilea), Amy Tung (Egilea), Patrick Gillard (Egilea), Anjana Lalla (Egilea), Victor W Nitti (Egilea), Christopher J Chermansky (Egilea)
• Formatua: Liburua
• Argitaratua: Becaris Publishing Limited, 2023-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Aim: The cost-effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared wi...